Dear respected authors,
if you can't find our response then please search our mail in your spam box and communicate with us to the following mail as well: firstname.lastname@example.org
30 Jan 2023
31 Jan 2023
Azerbaijan medical journal (ISSN: 0005-2523) - is a scopus indexed journal since 1961. The publisher of the journal is Izdatel'stvo Elm by WHO Office in Azerbaijan. Azerbaijan medical journal (AMJ) is also UGC approved. The journal publishes general medicine, health science, psychological, pharmaceutical journals and so on.
Aim and Scope
Azerbaijan Medical Journal
Azerbaijan Medical Journal (ISSN: 0005-2523) - is a peer-reviewed journal. The journal seeks to publish original research articles that are hypothetical and theoretical in its nature and that provide exploratory insights in the following fields but not limited to.
Azerbaijan Medical Journal
The Pharmacologic Role of Antioxidant Property of Beta carotene in Reducing Amikacin-Induced Nephrotoxicity
Investigation of Topical Nifedipine on Total Antioxidant Capacity and Mitochondrial Function During Facial Skin Wound Healing in Rabbits
Evaluation of functional outcomes of turn down Achilles tendoplasty with bone anchoring polypropylene suture using 18G hypodermic/spinal needle for the repair of Achilles tendon injuries.
Clinical and anti-inflammatory effects of fresh and Commercial Aloe Vera Gel on IL-6 levels in Oral Mucosal Burns induced in Rabbits
DETERMINATION OF NEURODEGENERATIVE MARKERS IN THE BLOOD SERUM OF PATIENTS WITH AUTOIMMUNE THYROIDITIS
Vitamin D is a steroid hormone regulating calcium-phosphorus homeostasis, immune response and brain function. In the past thirty years, an increasing number of cohort studies, metaanalyses and randomized controlled trials (RTCs) evaluated the serum levels of 25-hydroxyvitamin D [25(OH)D], which is considered the Vitamin D status biomarker, in patients affected by neurological, psychiatric and autoimmune diseases. Although an association between low 25(OH)D serum levels and the prevalence of these diseases has been found, it is still unclear whether the serum 25(OH)D measurement can be clinically useful as a biomarker for diagnosis, prognosis and predicting treatment response in neurodegeneration, mental illness and immune-mediated disorders. The lack of standardized data, as well as discrepancies among the studies (in the analytical methods, cut-offs, endpoints and study sets), weakened the findings achieved, hindered pooling data, and, consequently, hampered drawing conclusions. This narrative review summarizes the main findings from the studies performed on serum 25(OH)D in neurological, psychiatric and autoimmune diseases, and clarifies whether or not serum 25(OH)D can be used as a reliable biomarker in these diseases.
Pelviometric studies of 36 female pelves of a narrow configuration (18 pelves with a uniformly constricted shape and 18 - with a transversely narrowed) were conducted. The change in the dimensional characteristics of these pelves was studied depending on age (age range 16-60 years). It was found that both groups of constricted pelvic forms were not characterized by high variability in the age aspect and their sizes were relatively stable throughout life. At the same time, it was found that the parameters of the transversely shaped forms of the pelves were more susceptible to changes than the dimensions of the uniformly constricted configurations
PHYTO- AND PELOID PRODUCTS IN A COMPLEX SPA THERAPY OF PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE
Non-alcoholic fatty liver disease has emerged a major challenge because of it prevalence, difficulties in diagnosis, complex pathogenesis, and lack of approved therapies. As the burden of hepatitis C abates over the next decade, non-alcoholic fatty liver disease will become the major form of chronic liver disease in adults and children and could become the leading indication for liver transplantation. This overview briefly summarizes the most recent data on the pathophysiology, diagnosis, and treatment of non-alcoholic fatty liver disease. Ongoing clinical trials are focused on an array of disease mechanisms and reviewed here are how these treatments fit into the current paradigm of substrate overload lipotoxic liver injury. Many of the approaches are directed at downstream events such as inflammation, injury and fibrogenesis. Addressing more proximal processes such as dysfunctional satiety mechanisms and inappropriately parsimonious energy dissipation are potential therapeutic opportunities that if successfully understood and exploited would not only address fatty liver disease but also the other components of the metabolic syndrome such as obesity, diabetes and dyslipidemia.